- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02452450
Ibuprofen and Paracetamol Pharmacokinetic Study
May 22, 2015 updated by: Reckitt Benckiser Healthcare (UK) Limited
The purpose of this study was to determine rates of absorption of Ibuprofen and Paracetamol formulations.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
43
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 48 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age: > 18 to < 50 years.
- Sex: Male and female subjects are eligible for entry.
- Female subject of child bearing potential with a negative pregnancy test at the screening visit and willing to use an effective method of contraception, if applicable
- Female subject of non-child bearing potential with negative pregnancy test at the screening visit.
- Male subject willing to use an effective method of contraception.
- Status: Healthy volunteers with a body mass index of >18 and <30 kg/m2.
- Absence of relevant abnormalities in the clinical examination, ECG, drug and safety analysis.
- Subjects who have given written informed consent
Exclusion Criteria:
- Pregnant or lactating female subjects.
- A history of significant disease of any body-system.
- Any condition that may currently interfere with the absorption, distribution, metabolism or excretion of drugs.
- A history of allergy or intolerance (including angio-oedema, urticaria, bronchospasm and rhinitis) related to treatment with ibuprofen, aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs), paracetamol, or the excipients of the formulations.
- A history of peptic or duodenal ulcers or gastro-intestinal bleed or upper gastro-intestinal bleed, or other significant gastro-intestinal disorders.
- A history of frequent dyspepsia, e.g., heartburn or indigestion.
- A history of migraine.
- A history of psychotic illness, attempted suicide or parasuicide.
- Current smokers and ex-smokers who have smoked within 6 months.
- A history of drug abuse (including alcohol).
- High consumption of stimulating drinks
- Those with positive drugs of abuse screen including alcohol on any occasion throughout the study.
- Ingestion of a prescribed drug at any time in the 14 days before dosing with study medication (excluding hormonal contraceptives and hormone replacement therapy), or consumption of enzyme inhibitors or inducers during the previous month (such as barbiturates, carbamazepine, erythromycin, phenytoin, etc).
- Ingestion of an over-the-counter preparation within 7 days before dosing with study medication, including herbal medications, vitamin/fish oil supplements, ibuprofen and other NSAIDs and paracetamol.
- Donation of blood in quantity in the previous 12 weeks before enrolment into the study
- Known human immune deficiency virus (HIV) positive status, or a positive viral serology screen.
- Topical use of ibuprofen within 7 days before dosing with study medication
- Those previously randomised into this study.
- Employee at study site.
- Partner or first degree relative of the investigator.
- Those with an ibuprofen level > 10 ng/ml as determined at pre-study screening visit 2 (Part 2 (Pivotal Phase) of the study only).
- Those who are unwilling to consume gelatin of animal origin (Part 2 (Pivotal Phase) of the study only).
- Those who have participated in a clinical trial in the previous 12 weeks
- Those unable in the opinion of the Investigator to comply fully with the study requirements.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Paracetamol
|
|
Experimental: Ibuprofen lysine
|
|
Experimental: Ibuprofen sodium
|
|
Experimental: Ibuprofen liquid capsules
|
|
Active Comparator: Ibuprofen acid
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to the maximum concentration (Cmax) of the reference Ibuprofen
Time Frame: 0-4hr
|
0-4hr
|
Time to the first extrapolated non-zero concentration (Tlag)
Time Frame: 0-4hr
|
0-4hr
|
Time to the maximum concentration (Tmax)
Time Frame: 0-4hr
|
0-4hr
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to the lower therapeutic level reaching at least 5 µg/ml (T5.0) for ibuprofen and paracetamol
Time Frame: 0-4hr
|
0-4hr
|
Time to the mid therapeutic level reaching at least 8.4 µg/ml (T8.4) for ibuprofen and 10 µg/ml (T10.0) for paracetamol
Time Frame: 0-4hr
|
0-4hr
|
Time to the higher therapeutic level reaching at least 10.0 µg/ml (T10.0) for ibuprofen and 20 µg/ml (T20.0) for paracetamol
Time Frame: 0-4hr
|
0-4hr
|
Partial area under the curve (AUCs) at each nominal blood sampling time-point
Time Frame: 0-4hr
|
0-4hr
|
The area under the curve up to the median Tmax for the ibuprofen reference product (AUCTmaxRef)
Time Frame: 0-4hr
|
0-4hr
|
The plasma concentration at each planned nominal time-point (Cn)
Time Frame: 0-4hr
|
0-4hr
|
The maximum plasma concentration (Cmax)
Time Frame: 0-4hr
|
0-4hr
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2014
Primary Completion (Actual)
October 1, 2014
Study Completion (Actual)
October 1, 2014
Study Registration Dates
First Submitted
May 20, 2015
First Submitted That Met QC Criteria
May 20, 2015
First Posted (Estimate)
May 22, 2015
Study Record Updates
Last Update Posted (Estimate)
May 27, 2015
Last Update Submitted That Met QC Criteria
May 22, 2015
Last Verified
May 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Antipyretics
- Acetaminophen
- Ibuprofen
Other Study ID Numbers
- NL1307
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteer Study
-
Atea Pharmaceuticals, Inc.RecruitingHealthy Volunteer StudyUnited States
-
BenevolentAI BioRecruitingHealthy Volunteer StudyUnited Kingdom
-
Atea Pharmaceuticals, Inc.Completed
-
Atea Pharmaceuticals, Inc.Completed
-
Atea Pharmaceuticals, Inc.Hoffmann-La RocheCompletedHealthy Volunteer StudyCanada
-
Orion Corporation, Orion PharmaCompleted
-
Atea Pharmaceuticals, Inc.Not yet recruiting
-
Comanche BiopharmaRecruiting
-
BioAge Labs, Inc.CompletedHealthy Volunteer StudyNew Zealand
Clinical Trials on Paracetamol
-
GlaxoSmithKlineCompleted
-
University of HelsinkiFoundation for Paediatric Research, FinlandCompleted
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedHealthy SubjectsUnited States
-
Kamuzu University of Health SciencesCompleted
-
Baxter Healthcare CorporationCompletedPain, PostoperativeUnited Kingdom
-
GlaxoSmithKlineCompleted
-
Universitaire Ziekenhuizen KU LeuvenCompleted